Olaparib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-OLAPARIB |
|---|---|
| Type | Drug |
| Aliases | LynparzaОлапариб |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST DIS-OVARIAN DIS-PDAC DIS-PROSTATE |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | PARP inhibitor |
|---|---|
| Mechanism | Inhibits PARP1/2 — prevents repair of single-strand DNA breaks; in HRR-deficient (BRCA1/2 + other) tumors, leads to synthetic lethality via accumulated double-strand breaks that cannot be repaired by homologous recombination. |
| Typical dosing | 300 mg PO BID continuous until progression or unacceptable toxicity. Dose-modify for renal impairment (CrCl 31-50 → 200 mg BID; <30 not recommended). |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
PROfound trial: olaparib superior to enzalutamide/abiraterone in HRR-mutant mCRPC (BRCA1/2 highest benefit). Germline + somatic HRR testing required pre-start.
Used By
Regimens
REG-OLAPARIB-BREAST- Olaparib monotherapy (BRCA-mutant HER2- breast: metastatic OR adjuvant high-risk early)REG-OLAPARIB-MAINT-OVARIAN- Olaparib maintenance (HRD+ ovarian post-platinum response)REG-OLAPARIB-MAINT-PDAC- Olaparib maintenance (BRCA-mut PDAC post-platinum, POLO)REG-OLAPARIB-MONO- Olaparib monotherapy (mCRPC, HRR-mutant)